19 results about "Lymphangiogenesis" patented technology

A lymphangiogenesis inducing device includes: a puncture member comprising a distal end portion configured to puncture living tissue, and a through hole penetrating the puncture member along a central axis and extending from the distal end portion toward a proximal end; and a rod-shaped body inserted into the through hole and configured to be moved so as to protrude from the distal end portion. The rod-shaped body comprises a shaft portion, and a wound imparting structure comprising at least one protrusion located on the shaft portion and configured to impart a wound to the living tissue. The at least one protrusion has a protruding height from the shaft portion that increases when the at least one protrusion transitions from a state in which the at least one protrusion is located in the through hole to a state in which the at least one protrusion is located outside the through hole.

The present disclosure relates to systems, devices, and methods for subcutaneously cutting and treating tissue and cellulite with non-invasive acoustic waves. Embodiments of the present disclosure refer to systems, devices, and methods that use unfocused or planar, non-cavitating acoustic waves to induce physical effects in tissue such as dermis, fat, muscle, bone, blood vessels, liver tissue, etc. The physical effects include disruption of the fibrous extracellular matrix of the target tissue. Embodiments of the present disclosure include the application of multiple rapid acoustic pulses (e.g., shockwaves) to cause the breakdown of the fibrous extracellular matrix to reduce the appearance of cellulite or scarring in the treated area. Such unfocused or planar, non-cavitating acoustic waves can induce tissue responses such as reduced fibrosis, induction of angiogenesis or lymphangiogenesis, etc.

The present disclosure relates generally to the treatment of glaucoma and / or the reduction of elevated intraocular pressure (IOP). In particular, the present disclosure relates to compositions and methods for preventing or treating glaucoma, including primary glaucoma, by inhibiting factors associated with ocular lymphangiogenesis.

The rapid lymphatic vein communication device comprises an elastic tube body, notches which are symmetrical left and right are formed in the front end of the tube body, the notches are in the shape with the large front portion and the small rear portion, the tube thickness of the notch areas is sequentially decreased from back to front, the section of the tube body is in an oval shape, and the section of the tube body is in an oval shape. The upper end and the lower end of the tube body are provided with sheet-shaped protrusions on the right side of the notch, and lymphatic vessel generation promoting factors are embedded or coated on the tube wall of the tube body. According to the invention, lymphatic tissues and veins can be communicated efficiently and quickly; blood reflux and thrombosis are avoided; sewing operation is not needed or reduced; blood vessel blocking is not needed; specific growth factors contained in the kit can promote the generation of normal lymph lumen, form autologous biological lumen in the later period, and maintain long-term smoothness.

The present invention relates notably to a new isolated splice variant isoform of VEGF having pro-angiogenic and pro-lymphangiogenic activity, said isolated isoform comprising an amino acid sequence having at least 80%, preferably at least 95%, identity to the amino acid sequence of SEQ ID NO:1, preferably is VEGF222 / NF and consists of SEQ ID NO:1.

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistema magna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

The present disclosure relates to compounds that modulate the activity of transcription factor SOX18. More particularly, due to the modulation of transcription factor SOX18, the compounds present as useful therapies in the treatment of angiogenesis- and lymphangiogenesis- related diseases, disorders, or conditions.

In a lymphatic vessel neogenesis inducing device (10), a wound imparting part (14) is an edge part (40) formed on an outer peripheral part (34) of a rod-shaped body (12). The wound imparting unit (14) imparts a wound (52) to the target site (50) by rotating the rod-shaped body (12) about the central axis (22).

The invention relates to application of targeted epoxy eicosatrienoic acid or analogues thereof in promoting lymphatic neogenesis, and belongs to the technical field of biomedicine and lipid metabolism regulation. The epoxy eicosatrienoic acid promotes lymphatic endothelial cell paracrine and inflammation drainage by promoting lymphatic neogenesis. According to the invention, the combination of the EETs and the RACK1 target spot is found for the first time, lymphatic neogenesis is promoted by regulating and controlling the RACK1 related signal axis, and a new direction and theoretical basis are provided for subsequent research and development of drugs targeting the pathway for lymphatic vessel related diseases.

The invention belongs to the technical field of natural medicines, and particularly relates to application of ligustrazine in preparation of medicines for promoting lymphatic neogenesis and in-vitro activation of a VEGFC / VEGFR3 signal channel. It is found for the first time that ligustrazine can remarkably enhance the proliferation and migration capacity of HLECs, the number of lymphatic vessels in an infarct marginal area can be increased after MI, inflammatory cell infiltration can be relieved, the content of VEGFC in serum can be increased, expression of lymphatic vessel neogenesis related protein and genes can be promoted, the heart function can be improved, and myocardial cell damage can be relieved. The invention also finds that ligustrazine can activate a VEGFC / VEGFR3 signal channel. The invention provides a new active ingredient for developing a lymphatic vessel regulator for promoting lymphatic vessel neogenesis, provides a new thought and method for cardiac tissue repair and function improvement after MI, and also provides a new modeling drug for constructing a lymphatic metastasis model by activating a VEGFC / VEGFR3 signal channel in vitro and evaluating the curative effect of the anti-lymphatic metastasis drug.

A lymphangiogenesis inducing device includes: a rod configured to be inserted into a living tissue; and a wound application unit that is provided on the rod and configured to provide a fine wound to a target site of the living tissue. The wound application unit includes an edge formed on an outer periphery of the rod, and is configured to apply the wound to the target site upon rotation of the rod around a central axis.

The invention relates to an application of pachymic acid, and discloses an application of pachymic acid in a medicine for treating lymphedema. Pachymic acid can relieve lymphatic fibrosis and promote lymphatic formation by adjusting the level of cycloeicosatrienoic acid EETs, so that related symptoms of lymphedema are relieved, and a new molecular target is provided for treatment of lymphedema. The potential of traditional Chinese medicine in modern treatment application is highlighted, and pachymic acid is expected to become a candidate medicine for treating lymphedema.

The invention relates to the field of biological pharmacy and biological medicine, in particular to application of ICAM1 or a coding gene thereof in preparation of a product for treating or diagnosing inflammatory breast cancer. The invention provides application of an ICAM1 antibody-drug conjugate in preparation of a product. The product at least has one of the following effects: 1) treating inflammatory breast cancer; 2) inhibiting lymphatic vessel generation; and 3) the curative effect of the immune checkpoint inhibitor on the inflammatory breast cancer is improved. According to the application, it is determined that ICAM1 can be used as a potential therapeutic target of inflammatory breast cancer, and two ADCs, namely ICAM1-MMAE and ICAM1-DXd, related to ICAM1 are reasonably designed and developed. Experimental data confirm that ICAM1-DXd can be used as an optimal ADC for targeted therapy of inflammatory breast cancer, inhibits the generation of lymphatic vessels, and also shows a synergistic therapeutic effect after being combined with an immune checkpoint inhibitor PD1 for treatment. Finally, the application provides important basis and viewpoint for developing ADC drugs for treating inflammatory breast cancer.

Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and / or particular protein partners. Further, methods of treating angiogenesis- and / or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.

This invention discloses the application of lncRNA MAGE-A10-encoded short peptide in regulating lymph node metastasis and targeted therapy in bladder cancer, belonging to the field of biomedical technology. This invention focuses on the coding ability of long non-coding RNAs, using high-throughput sequencing and bioinformatics algorithms to screen for lncRNA MAGE-A10, which is highly expressed in lymph node metastasis-positive bladder cancer tissues. The coding ability was verified by predicting open reading frames, constructing expression vectors, and synthesizing specific antibodies. The encoded short peptide MAGE-A10-44aa was positively correlated with lymph node metastasis in bladder cancer and poor patient prognosis, and also promoted lymphangiogenesis and lymph node metastasis in bladder cancer. This confirms the biological role of the MAGE-A10-44aa short peptide in bladder cancer lymph node metastasis, providing a potential target for bladder cancer treatment.

The present invention relates to a method for reducing blood pressure by stimulating lymphatic vessel growth and / or lymphangiogenesis in the kidneys.

Lymphedema is a chronic condition causes by a lymphatic dysfunction that leads to the accumulation of fluid and fat in the limb. Here, the inventors identified the bioactive peptide apelin as good candidate to restore the lymphatic flow in lymphedema. They found a significant decrease in apelin expression in women lymphedematous arm compared to their normal arm. Using an apelin-knockout mouse model, they confirmed the crucial role of apelin as lymphedema was maintained more than 4 weeks after surgery and was associated with a lack of dermis lymphangiogenesis and increased dermal backflow. The inventors show that intradermal injection of apelin-lentivector significantly reduced limb swelling. This was associated with a reduction of dermis fibrosis and increase in lymphatic density. Importantly, apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells (LEC). This was associated with significant increase in E2F8-targeted gene expression through the direct binding of E2F8 on CCBE1 promoter in LEC. Taken together, the results show that apelin plays a key role in lymphedema and thus represents a novel partner for VEGF-C to prevent limb swelling and tissue fibrosis in lymphedema.

The present invention discloses the role of SEMA-123aa, encoded by circSEMA3C, in the targeted treatment of bladder cancer lymphatic metastasis, belonging to the field of biomedicine technology. The present invention uses the circRNA encoding product that drives bladder cancer lymphatic metastasis as the starting point, screens out circRNA-circSEMA3C that is upregulated in bladder cancer tissue through high-throughput sequencing, and confirms that SEMA3C-123aa, encoded by circSEMA3C, is positively correlated with the occurrence of bladder cancer lymphatic metastasis and can promote bladder cancer lymphangiogenesis and lymphatic metastasis, thereby revealing the biological role of SEMA3C-123aa in bladder cancer lymphatic metastasis and providing a theoretical basis and scientific basis for SEMA3C-123aa as an early diagnostic marker and new treatment target for bladder cancer lymphatic metastasis.